Loading
institutionsInstitution
Uniklinik Köln (CIO)
Uniklinik Köln runs the Centre for Integrated Oncology and leads lung cancer genomics via the Network Genomic Medicine.
Overview
Uniklinik Köln runs the Centre for Integrated Oncology at the University of Cologne and ranks thirty-second in the Newsweek/Statista oncology list. It leads lung cancer genomics through the Network Genomic Medicine Lung Cancer, associated with Wolf and Thomas, which has sequenced tens of thousands of non-small-cell lung cancer patients, and it leads chronic lymphocytic leukaemia research through Hallek and the German CLL Study Group; Reinhard Büttner, Barbara Eichhorst, Kirsten Fischer, Andreas Engert and Peter Borchmann are among the people OnCo lists here. OnCo links it to the German Hodgkin Study Group, to fellow centres in Düsseldorf and Essen and to Deutsche Krebshilfe. Whether a regional sequencing network can be copied in health systems without Germany's payer support is the question it raises. Its lung genomics and CLL programmes are the ones to read.
Location
Cologne, DE
Type
university · University of Cologne
Website
Newsweek 2026 oncology rank
#32
OnCo score
#73 · 44 points (28 Newsweek + 0 NCI + 16 from 8 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to University Hospital Cologne, including child institutions. 1,022 works · 8,958 citations · 64% open access · 12% clinical trials · 1% reviews.
Oncology works per year
1872022
2192023
1902024
2242025
2022026
Most works
- Christiane J. Bruns44 works
- Bastian von Tresckow42 works
- Hans Christian Reinhardt36 works
- Alexander Quaas36 works
- Peter Borchmann36 works
- Philipp Gödel32 works
- Udo Holtick31 works
- Freerk T. Baumann27 works
- Reinhard Büttner26 works
- Michael Hallek24 works
Most cited
- Lung cancer genomics
- CLL
Andreas Engert
Professor of Internal Medicine, Hematology and Oncology, University Hospital Cologne; former Chair, German Hodgkin Study Group
Hodgkin lymphomaTreatment de-escalationCooperative-group trials
Led the GHSG for two decades, running the HD10 to HD18 trials that cure over 90% of Hodgkin lymphoma with less treatment.
Barbara Eichhorst
Professor of Medicine and Head of the CLL Outpatient Clinic, University Hospital Cologne; Secretary, German CLL Study Group
Chronic lymphocytic leukaemiaTime-limited combinationsChemoimmunotherapy
Led CLL13 (GAIA), showing venetoclax-based fixed-duration therapy beats chemoimmunotherapy in fit CLL patients.
Jürgen Wolf
Medical Director, Lung Cancer Group Cologne; Head of Network Genomic Medicine
Lung cancerMolecular diagnostics networksMET and KRAS-targeted therapy
Built the Network Genomic Medicine that brought molecular testing to lung cancer patients across Germany, and led the capmatinib GEOMETRY trial.
Kirsten Fischer
Senior Physician and Study Coordinator, German CLL Study Group, University Hospital Cologne
Chronic lymphocytic leukaemiaFixed-duration therapyVenetoclax combinations
Led CLL14, which established one year of venetoclax plus obinutuzumab as a fixed-duration, chemotherapy-free CLL treatment.
Michael Hallek
Director, Department I of Internal Medicine, University Hospital Cologne; Head, German CLL Study Group
Chronic lymphocytic leukaemiaChemoimmunotherapyTargeted therapy trials
Leads the German CLL Study Group, whose trials (CLL8, CLL14, CLL13) set global standards for CLL treatment.
Peter Borchmann
Professor of Medicine and Head of the German Hodgkin Study Group, University Hospital Cologne
Hodgkin lymphomaPET-guided therapyAntibody-drug conjugates
Leads the German Hodgkin Study Group and HD21, which made BrECADD the most effective and least toxic regimen for advanced Hodgkin lymphoma.
Reinhard Büttner
Director, Institute of Pathology, University Hospital Cologne
Molecular pathologyLung cancer genomicsPredictive biomarkers
Molecular pathologist who co-founded Network Genomic Medicine and characterised lung cancer genomes.
Roman Thomas
Director, Department of Translational Genomics, University of Cologne
Cancer genomicsSmall-cell lung cancerLung cancer biology
Roman Thomas is a cancer genomicist who mapped the genomes of small-cell lung cancer.
Similar pages
- TrialCLL14
Shares Kirsten Fischer, Michael Hallek, Chronic lymphocytic leukaemia.
- TrialGHSG HD10
Shares Andreas Engert, Peter Borchmann, German Hodgkin Study Group.
- TrialCLL13 / GAIA
Shares Barbara Eichhorst, Michael Hallek, Chronic lymphocytic leukaemia.
- Key paperPositron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group
Shares Andreas Engert, Peter Borchmann, German Hodgkin Study Group.
- Key paperPET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
Shares Andreas Engert, Peter Borchmann, German Hodgkin Study Group.
- TrialGHSG HD18
Shares Andreas Engert, Peter Borchmann, German Hodgkin Study Group.
- TrialGHSG HD16
Shares Andreas Engert, Peter Borchmann, German Hodgkin Study Group.
- Key paperCLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients
Shares Kirsten Fischer, Michael Hallek, Chronic lymphocytic leukaemia.